Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients
The primary objective is to evaluate the antihypertensive efficacy of a fixed combination of Irbesartan/HydroChloroThiazide (CoAprovel) in Chinese moderate to severe hypertensive patients.
The secondary objective is to get systolic blood pressure and diastolic blood pressure goal attainment rate from CoAprovel in Chinese hypertensive patients.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients|
- Number of patients with controlled blood pressure [ Time Frame: At month 3 ] [ Designated as safety issue: No ]
- Adverse events [ Time Frame: Throughout the study period ] [ Designated as safety issue: Yes ]
- Systolic and Diastolic Blood Pressure [ Time Frame: At month 3 versus baseline ] [ Designated as safety issue: No ]
|Study Start Date:||April 2008|
|Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
Other Name: CoAprovel